aTyr Pharma
company in San Diego, United States
ATYR Nasdaq
ISIN US0021202025 SEC CIK 1339970 LEI 529900ENQUXMC5EBKO36
Follow aTyr Pharma
Weekly email: filings, results
Revenue, last quarter
$0
−100% vs same quarter last year
Net income
−$18.3M
+29.1% vs same quarter last year
EPS, diluted
−$7.43
+29.9% vs same quarter last year
Operating cash flow
−$9.5M
+53.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $190K | −$74.1M |
| FY24 | $235K | −$64M |
| FY23 | $353K | −$50.4M |
| FY22 | $10.4M | −$45.3M |
| FY21 | $0 | −$33.8M |
| FY20 | $10.5M | −$16.2M |
| FY19 | $422K | −$16.2M |
| FY18 | - | −$34.5M |
| FY17 | - | −$48.2M |
| FY16 | - | −$57.9M |
| FY15 | - | −$48M |
| FY14 | - | −$24.4M |
| FY13 | - | −$20M |
| FY12 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −40856.3% | −39009.5% |
| FY24 | −28899.6% | −27243.8% |
| FY23 | −15557.8% | −14274.5% |
| FY22 | −446.8% | −436.5% |
| FY21 | - | - |
| FY20 | −152.2% | −155.2% |
| FY19 | −5445% | −3844.5% |
| FY18 | - | - |
| FY17 | - | - |
| FY16 | - | - |
| FY15 | - | - |
| FY14 | - | - |
| FY13 | - | - |
| FY12 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$62.1M |
| FY24 | −$69.2M |
| FY23 | −$37.4M |
| FY22 | −$43.5M |
| FY21 | −$33.3M |
| FY20 | −$15.5M |
| FY19 | −$20.1M |
| FY18 | −$31.7M |
| FY17 | −$43.7M |
| FY16 | −$53.5M |
| FY15 | −$37.5M |
| FY14 | −$23.1M |
| FY13 | −$18M |
| FY12 | - |
- aTyr Pharma
- Healthcare median
Show the numbers
| Year | aTyr Pharma | Healthcare median |
|---|---|---|
| FY25 | −39009.5% | −30.6% |
| FY24 | −27243.8% | −47% |
| FY23 | −14274.5% | −58% |
| FY22 | −436.5% | −80.4% |
| FY21 | - | −71.8% |
| FY20 | −155.2% | −62.2% |
| FY19 | −3844.5% | −46.2% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |
| FY16 | - | −36% |
| FY15 | - | −37.8% |
| FY14 | - | −35.5% |
| FY13 | - | −37.1% |
| FY12 | - | −29.1% |